Health CarePharmaceuticals and Biotechnology
  • Price (EUR)46.36
  • Today's Change-0.22 / -0.47%
  • Shares traded6.10k
  • 1 Year change-0.09%
  • Beta1.0083
Data delayed at least 15 minutes, as of Jun 09 2023 12:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.

  • Revenue in EUR (TTM)1.11bn
  • Net income in EUR146.27m
  • Incorporated2017
  • Employees2.56k
  • Location
    Dermapharm Holding SELil-Dagover-Ring 7GRUENWALD 82031GermanyDEU
  • Phone+49 89641860
  • Fax+49 8 964186130
  • Websitehttps://ir.dermapharm.de/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Eckert & Zieglr Strahln und Mdzntchnk AG230.30m27.47m824.86m1.01k29.523.7420.983.581.321.3211.0710.420.59013.115.09235,966.207.138.608.5710.3746.9048.1512.0913.532.1524.630.194436.0723.189.90-15.2020.3449.5620.11
MorphoSys AG299.12m-72.84m950.62m623.00--9.78--3.18-2.14-2.148.762.840.12762.204.37475,546.90-3.11-10.92-3.48-12.3279.3788.74-24.35-77.843.46-2.500.7434--54.9333.0370.64--2.98--
Formycon AG42.50m35.99m1.12bn205.0020.002.9729.7026.463.503.503.0823.570.092425.083.66207,302.407.823.038.383.2928.4131.6184.6910.910.5908-554.000.07410.0016.077.86370.82--120.72--
Biotest AG517.40m-47.99m1.47bn2.23k--2.40--2.84-2.43-2.4326.1517.750.44991.353.68232,226.20-4.10-2.63-4.58-2.9823.8325.66-9.10-6.162.08-1.050.6496--0.0976.4250.01---22.75--
Dermapharm Holding SE1.11bn146.27m2.51bn2.56k17.074.3210.102.252.732.7320.7210.780.61291.3211.30433,965.307.9710.969.1412.6465.3360.1913.0014.391.236.880.661640.528.6817.01-35.9545.47-12.19--
Evotec SE751.45m-175.66m4.05bn4.95k--3.40--5.39-0.9942-0.99424.256.720.334520.764.30151,746.40-7.822.35-9.172.8323.1625.86-23.386.223.090.11590.29910.0021.5923.29-181.51--59.47--
Qiagen NV1.85bn327.37m9.61bn6.18k29.502.9018.495.181.421.428.0614.490.32072.055.68300,056.905.665.046.656.0263.9065.3917.6615.542.10115.560.3455---4.898.60-17.44--3.72--
Data as of Jun 09 2023. Currency figures normalised to Dermapharm Holding SE's reporting currency: Euro EUR
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.